KFSH&RC achieves gene therapy success, elevating clotting factor in hemophilia patients
Riyadh, November 13, 2023, The King Faisal Specialist Hospital and Research Centre (KFSH&RC) has successfully implemented advanced gene therapy for eight hemophilia patients, elevating clotting factor levels with a single dose. This breakthrough enables patients to lead daily lives without constant preventive treatments, significantly improving their quality of life. Gene therapy introduces functional genes to independently produce the deficient clotting factor, typically achieved with one intravenous dose. Hemophilia, caused by a genetic mutation, requires lifelong management, involving regular injections to prevent bleeding. KFSH&RC's achievement reflects its commitment to innovative treatments, enhancing patient experience and healthcare efficiency. The hospital is globally recognized for exceptional healthcare services and groundbreaking innovations, contributing to advancing medical technologies globally.